Archive for the 'Treatment' Category
November 17th, 2008. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience
Conclusion: CRS and HIPEC is a treatment option for peritoneal mesothelioma. Patients with epithelioid tumor who undergo complete cytoreduction may potentially benefit from this procedure.
November 14th, 2008. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia
No difference is seen combining platinum analogs with gemcitabine or pemetrexed. Platinum-based doublets might represent a therapeutic ceiling for cytotoxic chemotherapy in MPM.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Full Archive, Gemcitabine (Gemzar), Pemetrexed (Alimta), Pleural, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
November 11th, 2008. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma
With longer follow-up, mut+ may not only be predictive of survival but may represent a subset of patients whose disease may be responsive to TK-inhibitor therapy. Experiments confirming the activating properties of the novel mutations are warranted.
Posted in Chemotherapy, Determining Efficacy, EGFR, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
November 8th, 2008. Effective chemotherapy based on a chemosensitivity test for malignant pleural mesothelioma
Numerous chemotherapeutic agents have been tested in many clinical trials, but the response rate does not exceed 20% for most of the investigated regimens. Here we report a case of MPM in which the chemotherapy based on the chemosensitivity test was very effective on palliation with stable disease for a long time.
November 6th, 2008. Benign mesothelioma of peritoneum presenting as a pelvic mass
Postoperative recovery was satisfactory. At 3 years follow-up, patient is symptom-free.
November 5th, 2008. Malignant mesothelioma of the tunica vaginalis: a case report
The patient has not received additional therapy because there has been no evidence of metastasis. He has been free of disease 3 months postoperatively.
November 5th, 2008. Case of malignant mesothelioma presenting as a perineal and intrascrotal mass
The patient died six months after the initiation of therapy. To our knowledge, 24 cases of malignant mesothelioma in the perineum or intrascrotum were reported in Japan and this case was thought to be the 25th case in Japan.
November 5th, 2008. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma
Conclusions: Cytoreductive surgery combined with intraperitoneal chemotherapy appears to be the optimal treatment for selected patients with peritoneal mesothelioma. Increased familiarity with this condition's presentation and natural history, and knowledge of available treatment options, will hopefully facilitate treatment of these patients and expedite speedy referral to appropriate treatment centres.
Posted in Chemotherapy, Determining Efficacy, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
November 5th, 2008. Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study
Conclusion: The treatment yields good results with a high number of responses and long survival, and a low toxicity. The long survival of the epitheloid subgroup with good prognostic factors is as good as or even better than some studies on radical surgery or multimodal treatment, underlining the need of randomized studies to evaluate such treatment options.
Posted in Carboplatin, Chemotherapy, Determining Efficacy, Doxorubicin, Epithelioid, Full Archive, Gemcitabine (Gemzar), Surgery, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
November 1st, 2008. Genomic events associated with progression of pleural malignant mesothelioma
Imbalances seen by ROMA were confirmed by Affymetrix genome analysis in a subset of samples. © 2008 Wiley-Liss, Inc.
October 31st, 2008. Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors
The RD determined was pemetrexed 500 mg/m2 (d8) and paclitaxel 90 mg/m2 (d1 and d8), q21d. The combination was well tolerated and showed efficacy in thyroid carcinoma and mesothelioma.
October 31st, 2008. Diffuse malignant pleural mesothelioma: A multi-institutional clinicopathological study
Conclusions: The definitive diagnosis of early MPM is difficult, but establishing the best diagnostic modality would improve survival rates, since radical surgery is likely to be effective for resectable disease.
October 23rd, 2008. Malignant abdominal mesothelioma: defining the role of surgery
Conclusion: Surgical extirpation of MAM may be associated with significantly improved survival. All patients with MAM should be evaluated for potential surgical resection.
October 22nd, 2008. A case of non-tuberculous mycobacteriosis with pleurisy with a past history of dense exposure to environmental asbestos
A final diagnosis of NTM was confirmed via open biopsy of the lung. Our case suggests that in addition to tuberculosis, NTM should be taken into consideration as a complication of silicosis.
October 22nd, 2008. Interaction of onconase with the human ribonuclease inhibitor protein
This inhibition occurs with Ki = 0. 15 μM in a solution of low salt concentration.
October 22nd, 2008. A case of solid pseudopapillary tumour of the pancreas and malignant mesothelioma
Discussion: An abdominal computerised tomogram revealed pancreatic body mass arising. Pleural fluid cytology and a pleural biopsy failed to demonstrate malignancy. The pancreatic tumour was resected by distal pancreatectomy, segmental colectomy and splenectomy. The tumour was a solid pseudopapillary pancreatic tumour (SPT) with a high metastatic potential. The patient deteriorated and a repeat biopsy of the thickened pleura confirmed malignancy which was initially thought to be metastases from the SPT. Immunohistochemical staining confirmed malignant mesothelioma. The patient developed liver metastases and died 2 years from the diagnosis of metastatic disease.
Posted in Case Study, CT or CAT scan, Diagnosis & Differentiation, Full Archive, Immunohistochemistry or IHC, Pleural Effusion, Surgery, Survival, Symptoms & Symptom Management, Treatment, Type of Assessment: | No Comments »
October 18th, 2008. Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: A realistic treatment option?
Conclusion: The combination of carboplatin and pemetrexed may be a viable option in the treatment of malignant pleural mesothelioma.
Posted in Carboplatin, Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Full Archive, Pemetrexed (Alimta), Pleural, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
October 18th, 2008. Expression and Regulation of Epithelial Na+ Channels by Nucleotides in Pleural Mesothelial Cells
Furthermore, we found that both forskolin and cGMP increased the short-circuit currents in mouse pleural tissues. Taken together, our data demonstrate that the ENaC channels are biochemically and functionally expressed in human pleural mesothelial cells, and can be up-regulated by cAMP and cGMP.
October 18th, 2008. The cytotoxic ribonuclease onconase targets RNA interference (siRNA)
The data thus provide evidence that one of the targets of Onc is siRNA, likely within the RNA-induced silencing complex (RISC). In light of the findings that microRNAs are involved in tumor pathogenesis as well as in enhancing cell resistance to anticancer therapy the present data may provide explanation for both, the antitumor Onc activity and its propensity to enhance effectiveness of cytotoxic drugs.
October 17th, 2008. Down-regulation of Inhibition of Differentiation-1 via Activation of Activating Transcription Factor 3 and Smad Regulates REIC/Dickkopf-3–Induced Apoptosis
In summary, we first showed that both ATF3 and Smad were crucially and synergistically involved in down-regulation of Id-1, which regulated JNK phosphorylation in REIC/Dkk-3-induced apoptosis. Thus, gene therapy with REIC/Dkk-3 may be a promising therapeutic tool for MM.
|
|  |
